Glaukos Co. (NYSE:GKOS) Position Increased by Public Sector Pension Investment Board

Public Sector Pension Investment Board raised its holdings in shares of Glaukos Co. (NYSE:GKOS) by 5.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 116,605 shares of the medical instruments supplier’s stock after buying an additional 5,700 shares during the period. Public Sector Pension Investment Board’s holdings in Glaukos were worth $15,191,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in GKOS. Point72 Asset Management L.P. bought a new stake in Glaukos during the second quarter worth approximately $67,460,000. Primecap Management Co. CA boosted its holdings in Glaukos by 43.9% during the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock worth $144,483,000 after buying an additional 372,180 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Glaukos by 148.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock worth $48,805,000 after buying an additional 246,322 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Glaukos by 47.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after acquiring an additional 207,338 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its position in shares of Glaukos by 24.0% in the 2nd quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock valued at $95,112,000 after acquiring an additional 155,653 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on GKOS shares. Piper Sandler set a $140.00 price target on shares of Glaukos in a research report on Thursday, October 17th. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Wells Fargo & Company upped their price target on shares of Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Needham & Company LLC upped their price target on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, BTIG Research increased their target price on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $135.45.

Glaukos Stock Up 1.4 %

GKOS stock opened at $142.69 on Friday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $59.58 and a 12-month high of $146.86. The company has a 50 day moving average of $133.56 and a two-hundred day moving average of $124.39. The company has a market cap of $7.87 billion, a price-to-earnings ratio of -47.25 and a beta of 1.02.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. During the same quarter in the previous year, the business earned ($0.50) EPS. Glaukos’s quarterly revenue was up 23.9% compared to the same quarter last year. On average, equities analysts anticipate that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 8.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.